News, articles, and information on 3D 4D ultrasound.

GE Vs Medison ...

Retropubic versus Transobturator Midurethral Slings for Stress ...

2010-06-02
More vaginal perforations occurred in the transobturator-sling group than in the retropubic-sling group (13 vs. 6); the majority of those in the transobturator-sling group occurred when the in-to-out approach was used (10). ...

Human Parvovirus B19–Associated Myocarditis — NEJM

2010-03-31
we measured viral loads in endomyocardial biopsy specimens obtained from 498 patients (341 men and 157 women; mean [±SD] age, 46.93±15.85 years) with myocarditis2 or chronic dilated cardiomyopathy who were positive for parvovirus B19 on ... As shown in Figure 1B, acute parvovirus B19–associated myocarditis was characterized by a high mean viral load of 316000 genome equivalents (ge) per microgram of isolated nucleic acids, whereas the mean viral load of 709 ge per ...

Cardiac-Resynchronization Therapy — NEJM

2010-01-13
Correspondence from The New England Journal of Medicine — Cardiac-Resynchronization Therapy.

COMT Val158Met Genotype as a Risk Factor for Problem Behaviors in ...

2010-07-21
Authors: Albaugh MD, Harder VS, Althoff RR, Rettew DC, Ehli EA, Lengyel-Nelson T, Davies GE, Ayer L, Sulman J, Stanger C, Hudziak JJ. OBJECTIVE: To test the association between the catechol-O-methyltransferase (COMT) Val158Met ...

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension ...

2009-03-11
GE Bartsch, SK Broste, GA Grandits, RH Grimm, JD Neaton, KH SvendesnHydrochlorothiazide, chlorthalidone and mortality in the Multiple Risk Factor Intervention Trial.. Circulation 1984;70:Suppl II:II-360 ... Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. JAMA 2002;288:2981-2997[Erratum, ...

Cumulative Association of Five Genetic Variants with Prostate ...

2008-02-27
S. Lilly Zheng, M.D., Jielin Sun, Ph.D., Fredrik Wiklund, Ph.D., Shelly Smith, M.S., Pär Stattin, M.D., Ph.D., Ge Li, M.D., Hans-Olov Adami, M.D., Ph.D., Fang-Chi Hsu, Ph.D., Yi Zhu, B.S., Katarina Bälter, Ph.D., A. Karim Kader, M.D., .... Case subjects were classified as having advanced disease if they met any of the following criteria: a grade 3 or 4 tumor, spread to nearby lymph nodes and metastasis, a Gleason score of 8 or more, or a PSA level of more than 50 ng per ...

B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia — NEJM

2009-02-11
Among 43 patients with available information on Rai staging of disease (ranging from 0 [low risk] to I or II [intermediate risk] to III or IV [high risk]) at the time of the diagnosis of CLL, 40 patients (93%) had stage 0 or I, 2 patients ( 5%) had ..... In: Marti GE, Vogt RF, Zenger VE, eds. Proceedings of the USPHS workshop on laboratory approaches to determining the role of environmental exposures as risk factors for B-cell chronic lymphocytic leukemia and other B-cell ...

Acyclovir and Transmission of HIV-1 from Persons Infected with HIV ...

2010-02-03
The inclusion criteria for partners infected with HIV-1 were an age of at least 18 years, seropositivity for HIV-1 and HSV-2, a CD4 count of 250 or more cells per cubic millimeter, no conditions associated with acquired immunodeficiency ...

Apixaban or Enoxaparin for Thromboprophylaxis — NEJM

2010-07-24
The timing of the first apixaban administration (a mean [±SD] of 20.3±3.5 hours postoperatively in the Apixaban Dose Orally vs. Anticoagulation with Enoxaparin 2 [ADVANCE-1] study; ClinicalTrials.gov number, NCT00371683) or the total daily dose could affect the ... MR Lassen, GE Raskob, A Gallus, G Pineo, D Chen, RJ PortmanApixaban or enoxaparin for thromboprophylaxis after knee replacement.. N Engl J Med 2009;361:594-604. Free Full Text | Web of Science | Medline ...

A Randomized, Controlled Trial of Financial Incentives for Smoking ...

2009-02-11
The rate of participation in a smoking-cessation program was significantly higher in the incentive group than in the control group (15.4% vs. 5.4%, P